Abstract

The Wilms’ tumour-1 (WT1) protein is considered a prime target for cancer immunotherapy based on its presumptive immunogenicity and widespread expression across a variety of malignancies. However, little is known about the naturally occurring WT1-specific T-cell repertoire because self-derived antigens typically elicit low frequency responses that challenge the sensitivity limits of current detection techniques. In this study, we used highly efficient cell enrichment procedures based on CD137, CD154, and pHLA class I tetramer staining to conduct a detailed analysis of WT1-specific T cells from the peripheral blood. Remarkably, we detected WT1-specific CD4+ and CD8+ T-cell populations in the vast majority of healthy individuals. Memory responses specific for WT1 were commonly present in the CD4+ T-cell compartment, whereas WT1-specific CD8+ T cells almost universally displayed a naive phenotype. Moreover, memory CD4+ and naive CD8+ T cells with specificity for WT1 were found to coexist in some individuals. Collectively, these findings suggest a natural discrepancy between the CD4+ and CD8+ T-cell lineages with respect to memory formation in response to a self-derived antigen. Nonetheless, WT1-specific T cells from both lineages were readily activated ex vivo and expanded in vitro, supporting the use of strategies designed to exploit this expansive reservoir of self-reactive T cells for immunotherapeutic purposes.

Highlights

  • The Wilms’ tumour-1 (WT1) protein is a transcription factor expressed at high levels in several haematological malignancies and some solid tumours

  • The Wilms’ tumour-1 (WT1) protein is considered a prime target for cancer immunotherapy based on its presumptive immunogenicity and widespread expression across a variety of malignancies

  • We used highly efficient cell enrichment procedures based on CD137, CD154, and pHLA class I tetramer staining to conduct a detailed analysis of WT1-specific T cells from the peripheral blood

Read more

Summary

Introduction

The Wilms’ tumour-1 (WT1) protein is a transcription factor expressed at high levels in several haematological malignancies and some solid tumours. As a consequence of its oncogenic potential and presumptive immunogenicity, WT1 was ranked top in a list of tumour-associated antigens prioritized for cancer immunotherapy.[1] spontaneous T-cell responses against WT1 are induced in patients with leukaemia after allogeneic stem cell transplantation or donor lymphocyte infusions[2,3,4] and are associated with disease regression.[4] WT1-specific T cells may be involved in cancer immune surveillance. Little is known about the naturally occurring WT1-specific T-cell repertoire and its functional relevance in vivo, in part because of the exceedingly low frequencies of such cells in healthy donors. This knowledge gap potentially hinders the rational development of an effective WT1-directed T-cell therapy

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call